10:14 AM EST - Aeterna Zentaris Inc : Through its wholly-owned subsidiary Aeterna Zentaris GmbH, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it is continuing to expand its development pipeline by initiating a preclinical development program to develop parathyroid hormone fusion polypeptides (PTH) with delayed clearance based on proprietary intellectual property exclusively licensed by Aeterna from The University of Sheffield, U.K. Aeterna Zentaris Inc.
shares T.AEZS are trading up $0.08 at $1.35.
